ClinicalTrials.gg
CompletedNCT03390374Updated Jan 4, 2018

Oral Nystatin Prophylaxis to Prevent Systemic Fungal Infection in Very Low Birth Weight Preterm Infants

A Phase 4 interventional study of Nystatin Oral in Fungal Infections Systemic, sponsored by Dr Cipto Mangunkusumo General Hospital. Completed. Open to participants aged Up to 3 Days. Per ClinicalTrials.gov, last updated 2018-01-04.

Sponsored by Dr Cipto Mangunkusumo General Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 7 years 2 months after the study started (first participant enrolled Oct 2010, registered Dec 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
95
Allocation
Randomized
Ages
Up to 3 Days
Sex
All
01

Study summary

This study determines the effectiveness of oral nystatin as prophylaxis in order to prevent systemic fungal infection in very low birth weight preterm neonates. 47 participants received oral nystatin and 48 participants received sterile water as part of oral hygiene.

Read the detailed description

Oral nystatin is an effective and safe alternative fungal prophylaxis. Some previous studies (1 randomized controlled trial and 4 observational studies) showed that oral nystatin prophylaxis reduce fungal colonization and decrease risk of systemic fungal infection in very low birth weight infants.

Nystatin is a non-absorbable antifungal agent with minimal side effects that works by binding on the major component of fungus cell membrane and causes death of the fungus. Its efficacy as fungal prophylaxis is comparable with Fluconazole but does not linked to drug-induced liver injury.

To determine this effectivity, we recruit eligible neonates who are admitted in our neonatal intensive care unit and randomly assign them into 2 groups once noted written parental consent. One group is given nystatin via oral and/or orogastric tube and the other group only receives sterile water as part of oral hygiene. Weekly fungal surveillance cultures (oropharyngeal and rectal) are done to evaluate colonization. Further examinations (blood/cerebrospinal fluid/deep tissue/urine culture) are done once noted clinical signs of systemic fungal infections.

Data analysis is conducted with intent-to treat approach. Significance testing is done by chi-square or fisher's exact test as needed.

02

Conditions studied

  • Fungal Infections Systemic

Keywords

  • Nystatin
  • Fungal colonization
  • Systemic fungal infections
03

In context

Lead sponsor

Dr Cipto Mangunkusumo General Hospital is the lead sponsor of 39 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Up to 3 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Gestational age \<= 32 weeks and/or birth weight \<=1500 grams
  • 1 or more systemic fungal infection risk factors (antibiotic therapy, intravenous access, endotracheal tube, orogastric tube, urinary catheter, therapy, parenteral nutrition, theophylline therapy)

Exclusion criteria

Exclusion Criteria:

  • Suspected of having necrotizing enterocolitis within 72 hours after birth, cyanotic congenital heart disease, chromosomal defects, or critical conditions whom were not expected to live more than 72 hours after birth
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
95 participants (actual)

Study arms

  • Experimental
    Nystatin group

    Nystatin oral 1 mL (0.5 mL coated in oral cavity and the rest was given through orogastric tube) three times a day

    Drug: Nystatin Oral

  • No intervention
    Control group

    Sterile water 1 mL three times a day for oral hygiene

Interventions

06

What researchers measure

Primary outcomes

  1. Fungal colonization

    Weekly oropharyngeal and rectal fungal surveillance results are evaluated. Colonization is considered positive if yeast cells were found on either oral or rectal specimen

    Time frame: 1 to 6 weeks

  2. Systemic fungal infection

    Culture of blood, cerebrospinal fluid, deep tissue, or urine is evaluated in participants with symptoms/signs of systemic infection. Proven systemic fungal infection is defined as a positive blood, cerebrospinal fluid, deep tissue, or urine culture (\> 10.000 or more colony forming unit/mL from sterile bladder catheterization or suprapubic aspiration)

    Time frame: 1 to 6 weeks

Secondary outcomes

  1. Mortality rates

    Fungal and overall related mortality rates

    Time frame: 1 to 6 weeks

  2. Nystatin-related adverse drug reactions

    Any side effects of nystatin as reported in references

    Time frame: 1 to 6 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Rundjan L, Wahyuningsih R, Oeswadi CA, Marsogi M, Purnamasari A. Oral nystatin prophylaxis to prevent systemic fungal infection in very low birth weight preterm infants: a randomized controlled trial. BMC Pediatr. 2020 Apr 17;20(1):170. doi: 10.1186/s12887-020-02074-0. PubMed 32303210 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2010 to primary completion in Nov 2012, 25 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 27, 2017
First posted
Jan 4, 2018
StartActual
Oct 2010
Primary completionActual
Nov 2012
CompletionActual
Jan 2013
Last update
Jan 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03390374
Lead sponsor
Dr Cipto Mangunkusumo General Hospital
Responsible party
Lily Rundjan (Lily Rundjan, MD, Neonatologist, Dr Cipto Mangunkusumo General Hospital) — Principal investigator
First posted
Jan 4, 2018
Start date
Oct 2010
Primary completion
Nov 2012
Completion
Jan 2013
Last update
Jan 4, 2018

Study contacts

Lily Rundjan, MD
principal investigator · Dr Cipto Mangunkusumo General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nystatin

Start the discussion